Currently submitted to: JMIR Preprints
Date Submitted: May 8, 2020
Open Peer Review Period: May 8, 2020 - Apr 23, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Exposure to Morning Sunlight/Ultraviolet B (UV-B) Radiations (290–320nm) Decreases the Risk of COVID-19: India
ABSTRACT
The novel coronavirus 2019-nCoV/SARS-CoV-2 that has caused the outbreak of the coronavirus disease, COVID-19, has created an alarming situation around the world, including India. Vitamin D is a hormone precursor that plays an important role in adaptive immunity, cellular differentiation, maturation, and proliferation of immune cells. The optimum level of vitamin D could be a potential lead to fight against SARS-CoV-2 infection. In the Indian subcontinent, Vitamin D deficiency prevails in wide-ranging proportions, with a prevalence of 70%–100%. Vitamin D produced in the skin by sunlight/ultraviolet B (UV-B) radiation (290–320nm) may last in the blood twice compared with supplementary vitamin D, wherein consuming vitamin D through supplementary source may lead to toxicity. Balancing vitamin D levels between normal ranges will be effective and cheap to control and/or to prevent respiratory tract infections (RTIs). Although, if we talk about India, it is challenging to provide vitamin D through the supplementary source to every individual, and also it will not be affordable for people of below poverty line (BPL). Therefore, the optimum level of vitamin D could be a potential lead to fight against SARS-CoV-2 infection, which could be achieved by proper exposure to sunlight (preferably in the morning) for 10-20 min daily.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.